Clicky

Innate Pharma(IPH)

Description: Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.


Keywords: Medicine Biotechnology Clinical Medicine Immunology Immune System Antibodies Monoclonal Antibodies Cancer Treatment Cancer Immunotherapy Lung Cancer Inflammatory Diseases Head And Neck Cancer Advanced Solid Tumors Adenosine Immune Checkpoint Checkpoint Inhibitor Chronic Spontaneous Urticaria Peripheral T Cell Lymphoma Bullous Pemphigoid

Home Page: www.innate-pharma.com

117, Avenue de Luminy
Marseille, 13009
France
Phone: 33 4 30 30 30 30


Officers

Name Title
Dr. Mondher Mahjoubi M.D. Chairman of Exec. Board & CEO
Mr. Yannis Morel Ph.D. Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board
Dr. Herve Brailly Co-Founder & Chairman of Supervisory Board
Dr. François Romagné Ph.D. Founder
Mr. Eric Vivier D.V.M., M.B.A., Ph.D. Founder, Sr. VP & Chief Scientific Officer
Dr. Marc Bonneville Ph.D. Founder
Mr. Jean Jacques Fournié Ph.D. Founder
Mr. Alessandro Moretta M.D., Ph.D. Founder
Mr. Frederic Lombard M.B.A. Sr. VP & CFO
Ms. Odile Belzunce VP of Compliance & Operations

Exchange: PA

Country: FR

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.4342
Price-to-Sales TTM: 3.0375
IPO Date: 2006-11-01
Fiscal Year End: December
Full Time Employees: 213
Back to stocks